Inhaled corticosteroid for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
Background: The efficacy of inhaled corticosteroid (ICS) in the treatment of patients with COVID-19 has been evaluated in randomized controlled trials (RCTs), however, their findings are not consistent. Methods: PubMed, Embase, Cochrane Library, ClinicalTrials.gov, Scopus, Web of Science and Google...
Main Authors: | Chin-Wei Hsu, Mei-Chuan Lee, Yi-Ming Hua, Chih-Cheng Lai, Hung-Jen Tang, Chien-Ming Chao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Journal of Microbiology, Immunology and Infection |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118223001299 |
Similar Items
-
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
by: Janson C, et al.
Published: (2017-10-01) -
Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis
by: Chi-Kuei Hsu, et al.
Published: (2022-12-01) -
Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study
by: Kuan-Chih Kuo, et al.
Published: (2022-09-01) -
Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Pulmonary Disease in Chronic Obstructive Pulmonary Disease: Findings from a Nationwide Population-Based Study
by: Iseul Yu, et al.
Published: (2023-06-01) -
Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
by: Tsan-Ming Huang, et al.
Published: (2020-09-01)